Faulty Bioequivalence Studies Lead to Hundreds of Drug Suspensions in Europe

Jul 27, 2015, 00:00 by Michael Croft
WSJ Pharmalot | The European Union has accepted a recommendation to suspend hundreds of drugs that were authorized for use based on what regulators called "flawed" studies conducted by GVK Biosciences, a clinical research organization based in Hyderabad, India.

July 27, 2015 | The European Union has accepted a recommendation to suspend hundreds of drugs that were authorized for use based on what regulators called "flawed" studies conducted by GVK Biosciences, a clinical research organization based in Hyderabad, India. WSJ Pharmalot